Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Receives A$2.5 Million R&D Tax Incentive from French Government (ASX:IMM)

SYDNEY, AUSTRALIA – October 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy...read more

Immutep Announces Data Presentations at Upcoming Industry Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – October 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy ...read more

Immutep Announce Change of Director's Interest Notice - Mr Meyers (ASX:IMM)

Appendix 3Y For further information please download the attached PDF:

Immutep Announce Change of Director's Interest Notice - Mr Chamberlain (ASX:IMM)

Appendix 3Y For further information please download the attached PDF:

Immutep Announce Appendix 3B (ASX:IMM)

Appendix 3B New issue announcement, application for quotation of additional securities & agreement For further information please download the attached PDF:

Imugene Announce Cancer Vaccine Combinations Presented at ESMO (ASX:IMU)

European Society of Medical Oncology Congress Presentations Show B-Cell Vaccine Combinations Inhibit Cancer Growth in Preclinical Models SYDNEY, Australia, 1 October 2019: Imugene Limited (ASX:IMU)...read more

Imugene Announce Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO (ASX:IMU)

Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress SYDNEY, Australia, 1 October 2019: Imugene Limited (ASX:IMU), a clinical...read more

Immutep release Investor Presentation 2019 (ASX:IMM)

Investor Presentation 2019 The global leader in developing LAG-3 therapeutics To view the presentation please download the attached PDF:

Immutep Announce Notice of Annual General Meeting/Proxy Form (ASX:IMM)

A MESSAGE FROM THE CHAIRMAN Dear Fellow Shareholder, It is my pleasure to invite you to join Immutep’s Board and Management at our 2019 Annual General Meeting (AGM) on 1 November. ...read more

Immutep Announce Appendix 4G & Corporate Governance Statement (ASX:IMM)

Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations For further information please download the attached PDF:

Immutep Announce Annual Report to shareholders (ASX:IMM)

Annual Report 2019 To view the report please download the attached PDF:

Immutep expands Part A of TACTI-002 due to positive data (ASX:IMM)

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-...read more

Immutep Announce Annual Report filed on Form 20-F with SEC (ASX:IMM)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 To view the report please download the attached PDF:

Immutep to receive £4M milestone payment from GSK (ASX:IMM)

SYDNEY, AUSTRALIA – 23 September 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherap...read more

Immutep Announce Japanese Patent Grant for LAG525 Antibody (ASX:IMM)

SYDNEY, AUSTRALIA – 17 September 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 ...read more

Viewing: 1 - 15 of 200 Previous | Next